發(fā)布時間：2018-01-31 22:50

  本文關(guān)鍵詞： 芪仙骨合劑 糖尿病性骨質(zhì)疏松癥 中醫(yī)證候積分 骨密度　出處：《寧夏醫(yī)科大學》2017年碩士論文　論文類型：學位論文

【摘要】：目的通過觀察芪仙骨合劑對糖尿病性骨質(zhì)疏松癥患者中醫(yī)證候積分、骨密度、骨代謝生化指標、血糖、血液流變學及血脂等指標,以探討其臨床療效及其安全性。方法選擇2015年6月~2016年3月就診于我院,符合診斷標準的住院患者70例。分組采用隨機單盲法,分為治療組與對照組,每組各35例,均予兩組患者基礎(chǔ)治療。在此基礎(chǔ)上,對照組給予口服骨疏康膠囊治療,治療組給予口服芪仙骨合劑治療,療程為180天。試驗結(jié)束時,觀察并比較兩組治療前、后的中醫(yī)證候積分、骨密度、骨代謝生化指標、血糖、血脂、血液流變學等各項指標,并進行評價,統(tǒng)計軟件采用SPSS19.0進行數(shù)據(jù)分析。結(jié)果1.通過對70例患者的觀察,兩組在治療前對比一般資料具有可比性,無統(tǒng)計學差異(P0.05)�？傆行时容^,對照組總有效率為65.71%,治療組總有效率為88.57%,差異有統(tǒng)計學意義(P0.05),說明芪仙骨合劑總體臨床療效優(yōu)于骨疏康膠囊。2.中醫(yī)證候積分的比較,治療組與對照組在治療后中醫(yī)癥候積分均有減少(P0.05),兩組間比較,治療組中醫(yī)癥候積分較對照組減少明顯(P0.05),說明芪仙骨合劑在改善患者臨床癥狀方面較骨疏康膠囊療效更佳。3.骨密度的比較,治療組與對照組在治療后,患者骨密度均提高,兩組間比較,治療組骨密度較對照組增加明顯,差異有統(tǒng)計學意義(P0.05);因此,在增加患者骨密度方面治療組療效顯著。4.經(jīng)過治療后兩組患者血流變學指標及總膽固醇、甘油三酯、低密度脂蛋白均有所改善,且治療組較對照組療效更佳,差異有統(tǒng)計學意義(P0.05)。5.在實驗過程中無不良反應,且無不良事件發(fā)生,治療期間的安全性指標未見顯著性改變。結(jié)論運用芪仙骨合劑治療脾腎兩虛夾瘀型糖尿病性骨質(zhì)疏松癥,可顯著改善患者的臨床癥狀,改善骨密度、脂代謝及糖代謝,未見不良反應及不良事件,說明芪仙骨合劑治療糖尿病性骨質(zhì)疏松癥安全有效。
[Abstract]:Objective to observe the TCM syndromes integral, bone mineral density, biochemical index of bone metabolism, blood sugar, hemorheology and blood lipid in patients with diabetic osteoporosis treated with Qixianguo mixture. Methods from June 2015 to March 2016, 70 inpatients who met the diagnostic criteria were selected. Divided into treatment group and control group, each group of 35 cases, both groups were given basic treatment. On this basis, the control group was given oral Gushukang capsule treatment, the treatment group was given oral Qi-Xiangugu mixture treatment. The course of treatment was 180 days. At the end of the experiment, the TCM syndromes score, bone mineral density, bone metabolism biochemical index, blood glucose, blood lipid and hemorheology were observed and compared before and after treatment in the two groups. Statistical software SPSS19.0 data analysis. Results 1. Through the observation of 70 patients, the two groups before treatment compared with the general data are comparable. 2. The total effective rate was 65.71 in the control group and 88.57 in the treatment group. The difference was statistically significant (P 0.05). It shows that the overall clinical efficacy of Qixian Gu mixture is better than that of Guxukang capsule .2.Compared with the traditional Chinese medicine syndromes integral, the treatment group and the control group have reduced the TCM symptom score after treatment, and the comparison between the two groups. Compared with the control group, the TCM symptom score of the treatment group decreased significantly (P 0.05), which indicated that Qixian Gu mixture was better than Guxukang capsule in improving the clinical symptoms of the patients. After treatment, the BMD of the patients in the treatment group and the control group were all increased. Compared with the control group, the BMD in the treatment group was significantly higher than that in the control group, and the difference was statistically significant (P 0.05). Therefore, in the increase of bone mineral density in the treatment group significantly. 4. After treatment, the two groups of patients with hemorheology and total cholesterol, triglyceride, low density lipoprotein have improved. The therapeutic effect of the treatment group was better than that of the control group, and the difference was statistically significant (P 0.05). There were no adverse reactions and no adverse events occurred in the course of the experiment. Conclusion Qixiangui mixture can significantly improve the clinical symptoms and bone mineral density in treating diabetic osteoporosis with deficiency of spleen and kidney. Lipid metabolism and glucose metabolism, no adverse reactions and adverse events, which indicated that Qixianguji was safe and effective in the treatment of diabetic osteoporosis.
【學位授予單位】：寧夏醫(yī)科大學
【學位級別】：碩士
【學位授予年份】：2017
【分類號】：R259

【參考文獻】

相關(guān)期刊論文 前10條

1 黎敏;劉少玲;陳永華;;中西醫(yī)結(jié)合治療糖尿病性骨質(zhì)疏松療效觀察[J];實用中醫(yī)藥雜志;2016年12期

2 江帆;陳小莊;周曉莉;仝珊;;晚期糖基化終末產(chǎn)物、氧化低密度脂蛋白與老年糖尿病合并骨質(zhì)疏松癥的關(guān)系[J];檢驗醫(yī)學;2016年10期

3 王志國;胡詠新;徐書杭;張雙婕;王凌云;范海波;陳方慶;張家明;;甲狀旁腺激素和25羥維生素D對2型糖尿病患者并發(fā)骨質(zhì)疏松癥的影響及篩查價值[J];中國骨質(zhì)疏松雜志;2016年09期

4 周道成;趙恒俠;陳葉;劉德亮;鄭夏潔;張世茂;;中西醫(yī)結(jié)合治療糖尿病骨質(zhì)疏松20例臨床研究[J];江蘇中醫(yī)藥;2016年07期

5 劉舵;楊永利;雷婷;陳寶東;張勇杰;明磊國;;枸杞子乙酸乙酯提取物急性毒性及對切除卵巢大鼠骨質(zhì)疏松的防治作用[J];中國骨質(zhì)疏松雜志;2016年04期

6 賴青海;王琳琳;丁輝;余河水;曹滿;宋新波;;肉蓯蓉治療骨質(zhì)疏松癥研究進展[J];遼寧中醫(yī)藥大學學報;2016年03期

7 武玉亮;;帕米膦酸鈉和鈣劑聯(lián)合治療骨質(zhì)疏松的療效分析[J];臨床醫(yī)藥文獻電子雜志;2016年07期

8 杭照鋒;;中西醫(yī)結(jié)合治療糖尿病性骨質(zhì)疏松臨床療效研究[J];現(xiàn)代養(yǎng)生;2016年02期

9 鄭雁;苗明三;;雞內(nèi)金的現(xiàn)代研究特點分析[J];中醫(yī)學報;2015年12期

10 陳靜;王洪欣;;鈣劑聯(lián)合運動療法治療中老年婦女骨質(zhì)疏松癥療效分析[J];中國實用醫(yī)藥;2015年09期

，

本文編號：1480198